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Abstract
OBJECTIVES: Surgery for thymic epithelial tumours (TETs) with pleural involvement is infrequently performed. Thus, the value of surgical
therapy for primary or recurrent TETs with pleural involvement is not sufficiently defined yet.
METHODS: Twelve institutions contributed retrospective data on 152 patients undergoing surgery (1977–2014) on behalf of the ESTS
Thymic Working group. Outcome measures included overall (OS), cause-specific (CSS) and disease-free (DFS) survival as well as freedom
from recurrence (FFR).
RESULTS: In 70.4% of cases, pleural involvement was present at the time of primary intervention, whereas 29.6% had surgery for recurrent
disease involving the pleura. Pleural involvement resulted from thymomas (88.8%) and thymic carcinomas (11.2%). Forty extrapleural
pneumonectomies (EPPs), 23 total pleurectomies (TPs), and 88 local pleurectomies (LPs) were performed (completeness of resection in
76.8%). OS for the entire patient population at 1, 3, 5 and 10 years was 96.4%, 91.0%, 87.2% and 62.7%, respectively. There was no statistic-
ally significant difference regarding FFR and OS for patients with local or advanced disease undergoing EPP, TP or LP. Thymic carcinomas
in comparison with thymomas had a negative impact on OS [hazard ratio 6.506, P = 0.002], CSS and FFR. Incomplete resections predicted
worse OS [hazard ratio 6.696, P = 0.003].
CONCLUSIONS: Complete resection remains the mainstay of treatment for TETs with pleural involvement. Study populations treated with
EPP, TP and LP had similar survival that may be factual as observed, but in the presence of selection bias, we can further conclude from the
results that EPP, TP and LP are equally effective procedures. Procedural choice depends upon the extent of tumour distribution. EPPs, TPs
and LPs performed within a multimodality setting seem to be efficient procedures for local control of disease, as they yield excellent results
regarding OS, DFS, CSS and FFR.
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INTRODUCTION
Thymic epithelial tumours (TETs), namely thymomas and thymic
carcinomas (TCs), are rare neoplasms of thymic epithelial origin.
TETs present in different clinical stages and show a variety of
histological patterns. They are being treated in small numbers in
many different centres worldwide with heterogeneous diagnostic
and therapeutic algorithms. Advanced-stage TETs with pleural or
pericardial dissemination (Masaoka-Koga Stage IVA [1]) are en-
countered in only 6.8% of all patients with TETs [1–3]. The best
treatment for Stage IVA TETs still has to be defined. Complete
surgical resection is the mainstay of treatment for patients with
TETs. For patients with metastases of TETs to the visceral or par-
ietal pleura, different surgical techniques are employed. Surgical
techniques vary from extrapleural pneumonectomy (EPP) to total
pleurectomy (TP) or local pleurectomy (LP), and frequently resec-
tions are combined with chemotherapy (ChT) and/or radiother-
apy (RT) [4, 5]. In general, the indication to perform EPP is the
finding of numerous visceral and parietal pleural and pericardial
implants (and pulmonary nodules) that cannot be locally re-
sected [6]. TP is the removal of all parietal, mediastinal and dia-
phragmatic pleural surfaces and pericardium with or without
resection of the diaphragm. The decision to perform TP is made
when visceral pleura and lung are not affected by malignant dis-
ease. LP is metastasectomy (local resection) of pleural implants
without removal of all pleural surfaces. It is performed for mono-
or oligometastatic disease.
The value of surgical therapy with or without ChT and/or RT
for primary or recurrent thymic tumours with pleural involve-
ment is not sufficiently defined yet, due to limitations in the
available data. In this collaborative effort, members of the
European Society of Thoracic Surgeons (ESTS) Thymic Working
Group retrospectively collected data on patients undergoing
thoracic surgical procedures for primary and recurrent thymic tu-
mours with pleural involvement. The current work reflects the
former and current practice patterns of European and Canadian
thoracic surgery institutions treating TETs with pleural and/or
pericardial involvement.
MATERIALS AND METHODS
On behalf of the ESTS Thymic Working Group, emails were sent
to ESTS members to ask for participation on this retrospective
data collection in the treatment of patients with TETs with pleural
involvement. Respondents received a detailed standardized ques-
tionnaire (Supplementary Material, Table S1). In this collaborative
effort, a total of 152 patients with pleural disease of TETs were re-
ported by 12 institutions from 8 countries. All institutions were
specialized thoracic surgery centres routinely performing surgery
on patients with TETs. The reported patients were diagnosed and
operated between February 1977 and November 2014 (90% of
patients between 1 January 2001 and 30 November 2014,
Supplementary Material, Table S2).
Each institution obtained ethical approval from its ethics committee.
Study flow
There were coherent data for survival analysis on all 152 patients
and on 115 patients with complete resection for analysis of free-
dom from recurrence (FFR; Fig. 1).
Statistics/outcome analysis
Definitions of recurrence and outcome measures were reported
as recommended by the International Thymic Malignancies
Interest Group [7]. Overall survival (OS) was calculated as the pri-
mary outcome from the date of surgery (first pleural surgery,
Fig. 1) to the date of death of any cause. Patients without an
event were censored at the last time point known to be alive.
Disease-free survival was analysed from the date of surgery (first
pleural surgery) to the date of recurrence or death from any
cause (DFS) [8]. The end-point of interest for cause-specific sur-
vival (CSS) was defined as death from TET (censored observa-
tions: unrelated deaths and unknown cause of death) [7]. FFR was
calculated only in patients after complete surgical resection (R0)
from the date of surgery (first pleural surgery) to the date of re-
currence and full information on recurrence status [9]. Log-rank
tests were employed to compare whole Kaplan–Meier curves.
Differences at 1, 3, 5 and 10 years were reported descriptively.
Statistical methods are detailed further in the Supplementary
Material.
RESULTS
Institutions contributed a median of 11 patient cases (range
2–38; Supplementary Material, Table S2).
The median follow-up time for the entire patient cohort was
52 months [range 0–265; 95% confidence interval: 32.0–72.0].
The study cohort consists of 2 types of patients undergoing
surgery for pleural disease of TETs. Patients with pleural disease
Figure 1: Flow chart illustrating the assignment of patients to different end-
points. TETs: thymic epithelial tumours.
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at primary diagnosis (70.4%) as well as patients with pleural dis-
ease who had previous surgery for a TET (without involvement of
the pleura [29.6%]) were included in the study (Fig. 2). Mean age
at surgery for pleural disease was 47.3 years for the cohort
undergoing primary surgery for pleural disease of TETs and 54.6
years for patients with surgery for their first recurrent disease to
the pleura. Forty patients (26.3%) had 1 TET resection before the
first surgery of pleural disease (3 patients had 2 surgeries, 1 pa-
tient had 3 surgeries and 1 patient had 4 surgeries before pleural
dissemination, respectively).
Clinical data
Basic demographic data are presented in Table 1. For initial
symptoms (51.3%), diagnostic imaging, tumour location and pre-
operative biopsy (68.4%), see Supplementary Material, Table S3.
Myasthenia gravis (MG) was reported in 47 patients (30.9%); for
other autoimmune diseases (7.2%) and other malignancies, see
Supplementary Material. Seventeen patients (11.2%) were
diagnosed with TC and 135 (88.8%) with thymoma. Patients were
reported in pathological Masaoka–Koga Stages I (3.4%), II (6.1%),
III (20.5%), IVA (65.0%) and IVB (4.8%) at their first surgery. The
frequency of thymomas and TCs according to World Health
Organization histology was B2 (33.6%), B3 (23.9%), B1 (13.0%),
combined B2/B3 (11.6%), TC (10.3%), AB (4.1%), B1/B2 (2.0%), A
(0.7%) and combined B3/TC (0.7%) (Supplementary Material,
Table S4).
Surgery
Thymectomy information
Primary surgery for thymic epithelial tumours without involvement
of the pleura (Scenario 1): There were 3 TET resections (thymo-
mectomies) without thymectomy, 5 thymomectomies combined
with basic thymectomies (removal of thymic lobes) and 22 thy-
momectomies in conjunction with extended thymectomies (basic
thymectomy plus resection of mediastinal and cervical fatty tis-
sue). All patients had a recurrence to the pleura (Fig. 2).
Primary pleural surgery (Scenario 2): There was 6 thymomecto-
mies, 1 thymomectomy combined with basic thymectomy (re-
moval of the thymic lobes) and 64 thymomectomies in
conjunction with extended thymectomies. There were 3 recur-
rences after thymomectomy only (50%), after thymomectomy
plus basic thymectomy 1 (100%) and thymomectomy combined
with extended thymectomy 26 (49.0%).
Surgery for pleural disease of thymic epithelial tumours:
surgical approach, type and completeness of resection
Different surgical approaches were chosen to resect TETs with
pleural involvement (Table 2). For the resection of pleural disease,
EPP was performed in 26.5%, TP in 15.2% and LP in 58.3% of
Figure 2: Primary pleural surgery and surgery for recurrent pleural disease. TETs: thymic epithelial tumours.
Table 1: Basic demographic and clinical parameters
n (%)
Total number of cases 152 (100)
female:male ratio 76:76 (50:50)
Age in years mean/median [range] 50.4/51.0 [22–75]
Pleural surgery for thymic epithelial tumours
Surgery for pleural recurrence 45 (29.6)
Primary pleural surgery 107 (70.4)
Diagnosis
Thymoma 135 (88.8)
Thymic carcinoma 17 (11.2)
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patients. EPP, TP and LP were performed in 32 cases (29.9%), 13
cases (12.1%, including 1 case of pleurectomy/decortication [P/D])
and 62 cases (57.9%) for primary pleural surgery (Scenario 2), re-
spectively. In patients with pleural surgery for recurrence (Scenario
1, first pleural surgery) EPP, TP and LP were carried out in 8 pa-
tients (18.2%) and 10 patients (22.7%, including 3 patients with P/
D) and 26 patients (59.1%), respectively (missing information: 1 pa-
tient). Completeness of resection was pathologically confirmed in
76 (71%, R0), incomplete resection in 16 (15%, R1) and 15 (14%,
R2) for primary pleural surgery. Completeness of resection for re-
current pleural surgery was reported as: 40 (90.9%, R0), 1 (2.3%,
R1) and 2 (4.5%, R2), respectively (missing information: 2 patients).
The mean number of resected pleural nodules was 7.7 [range
1–90]. Tumour invasion/adherence (Table 2).
Treatment of the diaphragm in patients with thymic
epithelial tumours and pleural involvement
In non-EPP patients, there were 52 patients with metastasis of TETs
to the diaphragm. Diaphragmatic resection was performed in 34
cases: 6 complete and 28 partial resections of the diaphragm (missing
information on the extent of resection in 2 cases). There were 16
pleurectomies of the diaphragm without resection of the diaphragm.
Diaphragmatic plication was performed in 5 patients due to
paralysis of the diaphragm as a result of oncologic phrenic nerve
resection.
Multimodal therapy
Neoadjuvant therapy was administered in 67 patients (62.2%),
pseudo-neoadjuvant therapy before surgery for recurrence in 15
patients (33.3%), adjuvant therapy in 68 patients (63.6%) and
pseudo-adjuvant therapy after surgery for recurrence in 10 pa-
tients (22.2%), respectively (Table 2). Neo- and pseudo-neoadju-
vant PAC ChT (planned protocol: cisplatin 50 mg/m2,
doxorubicin 50 mg/m2 and cyclophosphamide 500 mg/m2) was
administered in 45 patients of the 76 (59.2%) patients who
received ChT. For induction therapy (n = 65), the mean number
of administered ChT cycles was 4.15 (median 4, range 2–8).
Radiotherapy was administered in a neoadjuvant (8 patients),
pseudo-neoadjuvant (1 patient), adjuvant (63 patients) or pseudo-
adjuvant (5 patients) setting. The administered mean radiation dose
was 40.9 G [median 45 G, range 20–56 G] for neoadjuvant therapy
and 50.3 G [median 50 G, range 24–60 G] for adjuvant therapy.
Recurrence after surgery with or without
chemo- and radiotherapy for pleural disease of
thymic epithelial tumours
The median time from primary surgery for a TET without involve-
ment of the pleura to surgery for recurrence of disease to the
pleura (first pleural surgery, Scenario 1) was 55.0 months.
The median time to recurrence after the first pleural surgery
(second recurrence in Scenario 1 and first recurrence in Scenario
2, see Fig. 2) was 46 months. Recurrence after complete resection
(R0) with or without ChT and/or RT for TETs with pleural involve-
ment occurred in 59 patients (51.3%). See Table 2 for type of re-
currence. The mean total number of recurrences after surgery for
pleural disease was 1.47 (median 1, range 1–9).
Table 2: Treatment modalities
n = 152 n (%)
Preoperative treatment
Neoadjuvant 67/107 (62.6)
Chemotherapy 59/67 (88.1)
Radiotherapy 5/67 (7.5)
Radiotherapy and chemotherapy 3/67 (4.4)
Pseudo-neoadjuvant 15/45 (33.3)
Chemotherapy 14/15 (93.3)
Radiotherapy 1/15 (6.7)
Radiotherapy and chemotherapy 0/15 (0.0)
Response to preoperative therapy
Neoadjuvant
Stable disease 5 (7.5)
Partial response 48 (71.6)
Progression 3 (3.9)
No information 11 (16.4)
Pseudo-neoadjuvant
Stable disease 1 (6.6)
Partial response 7 (46.6)
Progression 0 (0.0)
No information 7 (46.6)
Postoperative treatment
Adjuvant 68/107 (63.6)
Chemotherapy 5/68 (7.3)
Radiotherapy 49/68 (72.1)
Radiotherapy and chemotherapy 14/68 (20.6)
Pseudo-adjuvant 10/45 (22.2)
Chemotherapy 5/10 (50.0)
Radiotherapy 4/10 (40.0)
Radiotherapy and chemotherapy 1/10 (10.0)
Surgical approach
Thoracotomy 61 (40.4)
Sternotomy 65 (43.0)
Clamshell 6 (4.0)
Hemi-clamshell 16 (10.6)
Video-assisted thoracic surgery 3 (2.0)
Type of pleural surgery
Extrapleural peumonectomy 40 (26.5)
Local pleurectomy 88 (15.2)
Total pleurectomy 23 (58.3)
Invasion
Lung 91 (65.9)
Pericardium 76 (53.9)
Pleura
Parietalis 40 (28.2)
Visceralis 6 (4.2)
Diaphragmatic 11 (7.7)
Parietal/visceral/diaphragmatic 67 (47.2)
Diaphragm muscle 39 (27.7)
Superior vena cava 10 (7.1)
Thoracic wall 9 (6.4)
Phrenic nerve 33 (23.4)
Adherence
Lung 68 (47.6)
Pericardium 56 (39.2)
Diaphragmatic musculature 41 (28.7)
Aorta 8 (5.6)
Great vessels other than aorta 12 (8.4)
Residual tumour
R0 116 (77.3)
R1 17 (11.3)
R2 17 (11.3)
Recurrencea 115 (100)
No 56 (48.7)
Yes 59 (51.3)
Recurrence type 59 (100)
Local 15/59 (25.4)
Regional 30/59 (50.8)
Distant 9/59 (15.3)
Regional and distant 5/59 (8.5)
aRecurrences only after R0 resection were included in the analysis.
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Mortality during the first postoperative year
Two patients died during the first 30 days (perioperative mortality)
after pleural surgery for TETs (patients with TC suffered from pneu-
monia and acute respiratory distress syndrome after EPP; patient
with TC undergoing total pleurectomy died due to acute pulmonary
embolism and prolonged air leak). One patient with B2 thymoma
undergoing EPP died between 30 and 90 days postoperatively
(cause of death not tumour related). Two more patients died be-
tween 90 days and 1 year. A patient with TC after EPP died related
to progression of metastatic disease at 8 months, and another pa-
tient with B2 thymoma after EPP died from pneumonia resulting in
acute respiratory distress syndrome 10 months after surgery.
Complications
There were documented data on 103 patients on complications
or follow-up without complications. Of these, 59 patients had no
surgical complications. Complications allocated to their respect-
ive type of surgery (Supplementary Material, Table S5).
Survival analysis
Outcome: overall survival, cause-specific survival,
disease-free survival and freedom from recurrence
The number of events for survival analyses (n = 152) and analyses
of FFR (n = 115) is indicated in Fig. 1 (number of events for the re-
spective subgroup analyses is indicated in Figs 2 and 3). OS of
the entire patient cohort at 1, 3, 5 and 10 years was 96.4%,
91.0%, 87.2% and 62.7%, respectively. Accordingly, DFS, CSS and
FFR were calculated: DFS: 84.3%, 60.9%, 44.9% and 15.2%; CSS:
97.8%, 94.9%, 92.3% and 79.7%; FFR (n = 115) at 1, 3, 5 and 10
years was 83.1%, 57.9%, 43.0% and 22.2%, respectively (Fig. 3).
Analysis of OS at 3, 5 and 10 years revealed statistically signifi-
cant differences between primary pleural surgery and surgery for
pleural recurrence (P = 0.028, P = 0.023, P = 0.027, respectively).
Comparably, the analysis of OS at 3, 5 and 10 years revealed stat-
istically significant differences between complete and incomplete
resections: R0 vs R1/R2 (P = 0.032, P = 0.003, P = 0.001, respect-
ively). While there were no statistically significant differences in
FFR for the type of surgery: EPP vs TP vs LP, there were differ-
ences in OS [1-year: P = 0.010], DFS [3-year: P = 0.021 and 5-year:
P = 0.037] and CSS [1-year: P = 0.012 and 3-year: P = 0.041]. The
calculation of OS, DFS, CSS and FFR for thymomas versus TCs at
1, 3, 5 and 10 years revealed statistical significance for all analysis.
Analysis of OS and CSS revealed a statistically significant survival
advantage for patients with MG (10-year OS: P = 0.010; the 5 and
10-year CSS: P = 0.047 and P = 0.014, respectively; Fig. 4 and
Supplementary Material, Table S6). In non-EPP patients with
pericardial resection (n = 52), there was significantly worse sur-
vival at 10 years (OS at 1, 3, 5 and 10 years for pericardial resec-
tion yes (n = 52) vs no (n = 52): 98.0% vs 100.0% (P = 0.322), 93.3%
vs 100.0% (P = 0.082), 86.7% vs 97.0% (P = 0.082), and 55.1% vs
87.2% (P = 0.010), respectively.
Prognostic factors
Table 3 illustrates the analysis of predictors (univariable and mul-
tivariable analysis) using 3 end-points: OS, CSS and FFR.
Figure 3: Survival analysis: entire patient cohort. Overall survival (A), disease-free survival (B), cause-specific survival (C) and freedom from recurrence (D).
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Figure 4: Survival analysis: comparison of primary pleural surgery and pleural surgery for recurrence: OS (A), FFR (B), type of surgery: EPP vs TP vs LP: OS (C), FFR (D),
thymoma vs TC: OS (E), FFR (F), and completeness of resection: OS (G), FFR (H). EPP: extrapleural pneumonectomy; TP: total pleurectomy; LP: local pleurectomy; TC:
thymic carcinoma.
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At univariable analysis, the presence of MG was beneficial at
increasing OS [hazard ratio (HR) 0.234; P = 0.019], while TC, in-
complete resection, TC vs thymomas, primary pleural surgery vs
surgery for pleural recurrence, type of pleural surgery (EPP vs TP/
LP), preoperative and postoperative therapy had a negative im-
pact on OS.
TCs in comparison with thymomas at multivariable analysis
had a negative impact on OS [HR 6.506; P = 0.002], CSS [HR
13.144; P = 0.001] and FFR [HR 2.442; P = 0.027], respectively.
Further, incomplete resections predicted worse OS [HR 6.696;
P = 0.003] and male sex predicted worse FFR [HR 1.800; P = 0.033]
at multivariable analysis. In order to eliminate the potential
strong bias of incomplete resection on other predictors, we also
performed multivariable analysis only on patients after complete
resection (R0): negative impact on OS male sex [HR 3.176;
P = 0.025], TC [HR 3.988; P = 0.013], primary pleural surgery com-
pared with surgery for pleural recurrence [HR 4.132; P = 0.040];
no effect was found for MG, age, type of surgery, preoperative or
postoperative treatments. Analysis of multimodality therapy (all
patients with [pseudo-]neo- and [pseudo-]adjuvant therapy com-
bined: n = 126) vs surgery alone (n = 26) revealed no statistically
significant differences.
Univariable analysis for the number of resected nodules
(n = 122) with a cut-off value of 4 (median number of resected
nodules) for dichotomizing groups revealed no statistically sig-
nificant differences.
DISCUSSION
TETs are a rare and heterogeneous entity. Whereas for the lower
stages of disease, complete surgical resection has become the ac-
cepted standard and mainstay of treatment, little data exist about
the value of surgical resection in advanced stages. Especially for
Masaoka–Koga Stage IVA, which is defined by the presence of
pleural spread and metastasis, the value of surgical resection
Table 3: Univariable and multivariable analysis
Univariable Multivariable
95% CI 95% CI
HR P-value Lower Upper HR P-value Lower Upper
Overall survival
Sex (male) 1.508 0.322 0.669 3.397 2.438 0.092 0.865 6.871
Age (continuous) 1.026 0.161 0.990 1.063 1.017 0.395 0.978 1.058
Myasthenia gravis (yes) 0.234 0.019 0.069 0.790 0.551 0.459 0.114 2.666
TC vs thymoma 6.315 0.000 2.652 15.040 6.506 0.002 1.956 21.646
Incomplete resection 3.916 0.001 1.727 8.882 6.696 0.003 1.944 23.060
Pleural surgery
Primary pleural surgery vs pleural surgery for recurrencea 4.392 0.017 1.302 14.813 1.493 0.603 0.330 6.757
Type of pleural surgery
EPP vs LP + TP 2.351 0.040 1.041 5.312 2.491 0.122 0.784 7.913
Preoperative therapy (yes)b 3.086 0.013 1.271 7.463 1.495 0.427 0.554 4.032
Postoperative therapy (yes)c 2.558 0.030 1.093 5.988 1.733 0.293 0.622 4.831
Cause-specific survival
Sex (male) 1.740 0.331 0.569 5.325 3.206 0.128 0.715 14.372
Age (continuous) 1.041 0.108 0.991 1.093 1.039 0.197 0.980 1.101
Myasthenia gravis (yes) 0.022 0.110 0.000 2.387 0.000 0.952 0.000 171.39
TC vs thymoma 12.129 0.000 3.867 38.044 13.144 0.001 2.726 63.370
Incomplete resection 2.004 0.255 0.606 6.628 2.053 0.387 0.402 10.487
Pleural surgery
Primary pleural surgery vs pleural surgery for recurrencea 2.198 0.239 0.593 8.130 1.213 0.836 0.194 7.576
Type of pleural surgery
EPP vs LP + TP 2.301 0.155 0.729 7.265 1.063 0.934 0.252 4.488
Preoperative therapy (yes)b 2.179 0.180 0.697 6.803 1.072 0.914 0.593 3.788
Postoperative therapy (yes)c 2.066 0.203 0.675 6.329 1.020 0.976 0.288 3.613
Freedom from recurrenced
Sex (male) 1.541 0.096 0.926 2.566 1.800 0.033 1.050 3.086
Age (continuous) 1.007 0.523 0.985 1.031 1.009 0.504 0.983 1.036
Myasthenia gravis (yes) 0.623 0.090 0.361 1.077 0.661 0.208 0.346 1.260
TC vs thymoma 2.748 0.006 1.330 5.676 2.442 0.027 1.106 5.388
Pleural surgery
Primary pleural surgery vs pleural surgery for recurrencea 1.138 0.629 0.002 1.919 1.131 0.676 0.633 2.024
Type of pleural Surgery
EPP vs LP + TP 1.491 0.165 0.849 2.618 1.467 0.241 0.773 2.784
Preoperative therapy (yes)b 0.852 0.542 0.508 1.427 0.577 0.068 0.319 1.042
Postoperative therapy (yes)c 0.750 0.270 0.450 1.250 0.849 0.578 0.476 1.513
TC: thymic carcinoma; LP: local pleurectomy; TP: total pleurectomy; EPP: extrapleural pneumonectomy.
aAnalysis of primary pleural surgery versus pleural surgery for recurrence.
bPatients received (pseudo-)neoadjuvant therapy, including chemotherapy ± radiotherapy.
cPatients received (pseudo-)adjuvant therapy, including chemotherapy ± radiotherapy.
dFreedom from recurrence was analysed only for patients after R0 resection.
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remains in question. The reason for this lies in the low number of
cases that are usually seen in single institutions as well as in the
heterogeneity of the clinical presentation. Whereas some patients
present with only one or few well-defined and localized pleural
lesions, others have a diffuse pattern of pleural involvement and
few patients have the combination of pleural and intraparenchy-
mal tumour spread in the lung. Accordingly, surgical attempts for
radical resection vary from LP over TP to EPP (complete en bloc
removal of pleura, diaphragm and lungs).
The intention of this retrospective study among members of
the ESTS Thymic Working Group was therefore to accumulate a
sufficiently large cohort of patients that would allow for mean-
ingful statistical analysis and provide better insight and under-
standing of the role of surgical resection for TETs in Stage IVA.
The most important finding of this study was that complete
surgical R0 resection, regardless of which surgical method was
applied, as well as the histology of thymomas compared with
TCs, was predictive for improved OS at multivariable analysis.
Certainly the choice of the surgical procedure is dependent
from the underlying situation and extent of spread of disease. It
therefore appears evident that patients undergoing EPP were in
an even more advanced tumour situation, compared with pa-
tients in whom complete resection was achieved by TP or simple
LP. It is therefore even more remarkable that with the extended
surgical procedure of EPP, a similar positive effect on OS was
achieved in more advanced tumour situations, as with the some-
what more limited procedures in less advanced situations.
Better survival was evident in patients with surgery for recur-
rent disease to the pleura (first pleural surgery/Scenario 1). In this
patient cohort, 18.2% EPPs, 2.2% TCs and 6.8% incomplete resec-
tions were performed in contrast to 29.9% EPPs, 15.0% TCs and
29.9% incomplete resections in patients with primary pleural sur-
gery (Scenario 2). There is an obvious bias in disease severity and
the resulting invasiveness of the necessary surgical procedure
that may not allow a fair comparison of these patient cohorts.
Nevertheless, it demonstrates again the excellent outcome of sur-
gery for recurrent disease to the pleura [10]. One might also
speculate about different biology of TETs presenting with pleural
involvement at first diagnosis or that patients in institutional
follow-up programmes after thymic surgery (tertiary prevention)
are diagnosed earlier with recurrence than patients with TETs
with pleural involvement without prior thymic surgery (no pri-
mary prevention).
Different treatments and different reasons to treat the dia-
phragm in patients with TETs and pleural involvement can be dis-
tinguished. For metastases to the diaphragm, partial or complete
resection of the diaphragm or just pleurectomy of the diaphragm
can be performed. The reason to perform diaphragmatic surgery
is purely oncologic: metastasis to the diaphragmatic pleura with
our without involvement of diaphragmatic musculature. Despite
the respectable number of patients with this rare disease entity
and the multicentre nature of this work, no recommendation can
be given on whether just pleurectomy or full-thickness resections
will result in different outcomes concerning recurrence rates or
survival. Since patients with diaphragmatic involvement had con-
current nodules on other pleural sites, the isolated analysis of the
issue of diaphragmatic resection or pleurectomy cannot be se-
lectively answered (46.1% recurrences [12 of 26 R0 resections]
after complete or partial diaphragmatic resections vs 44.4% re-
currences [4 of 9 R0 resections] after diaphragmatic pleurectomy
only). Another indication for treatment of the diaphragm in this
patient cohort is in patients with tumour infiltration or
inseparable tumour adherence to the phrenic nerve. In cases
with obligatory demand for oncologic resection of the phrenic
nerve, diaphragmatic plication is performed to flatten the para-
lyzed dome of the diaphragm and thus provide sufficient space
for the lung to expand (functional reason).
Five-year OS of patients undergoing resection for pleural dis-
semination of TETs in studies with 5 to 21 patients was recently
reviewed and ranges from 43.1 to 92.3% [3]. In a recent retro-
spective study on behalf of the Japanese Association for Research
on the Thymus on 136 patients who underwent surgical resection
for TETs with pleural dissemination, Masaoka Stage IVA (n = 118)
and IVB (n = 18), 5-year OS was 83.5% [11]. OS of the entire pa-
tient cohort in the current study compares favourably with
87.2%.
A study of 229 patients with TC (Masaoka Stage I–IV, ESTS
database) identified 5- and 10-year OS rates of 0.61 and 0.37 and
5- and 10-year FFR rates of 0.60 and 0.43. At multivariate ana-
lysis, incomplete resections and advanced stage (Masaoka–Koga
Stage III–IV) had a negative impact on OS, P < 0.0001 and
P = 0.02, respectively. The authors concluded that surgical resec-
tion of TC should be undertaken whenever possible [9]. Five- and
10-year OS of patients with TC (n = 17) with pleural involvement
in the current study was comparable, 56.0% and 0% (6 deaths by
the end of 10 years), respectively.
Masaoka–Koga Stage III–IV, incomplete resection and non-
thymoma histology were identified to have a significant impact
on increasing recurrences and worsening survival in an ESTS co-
hort study (2030 patients). Administration of adjuvant therapy
after complete resection was associated with improved survival
[8]. Conversely, in a Japanese study on 1320 patients the value of
adjuvant therapy after complete resection was in doubt [2].
Masaoka Stage IVA patients (n = 118) with 10 or fewer pleural
nodules and macroscopic complete resection were reported to
have better prognosis (Japanese Association for Research on the
Thymus). In Stage IVA patients with complete resection, there
were no supportive data on the efficacy of ChT and/or RT [11].
Better OS and CSS of patients with MG may be explained by
looking at diagnosis, resection status and type of surgery (MG+:
2.1% TCs, 17.4% incomplete resections and 10.6% EPPs in com-
parison with MG-: 15.2% TCs, 25.0% incomplete resections and
33.7% EPPs). There was an obvious difference in disease severity
between the 2 study groups. In a study on 797 thymoma pa-
tients, a slight protective effect of MG on OS was observed that
was not confirmed by multivariate analysis [12]. In patients with
thymoma (Masaoka–Koga Stage I–IV), MG had an influence on
histology and stage presentation, but only stage had a prognostic
significance on OS and DFS [13]. Reasons for these observations
may be associated with earlier diagnosis of TETs in MG patients
(because of closer follow-up) or improvements in MG manage-
ment [13].
Ninety percent of patients (64 of 71) underwent extended
thymectomy at the time of primary pleural surgery (recurrence
rate: 49.0%). Six patients had thymomectomy only (50% recur-
rences). Only 20.6% of patients undergoing extended thymec-
tomy at primary pleural surgery had MG. Thus, general practice
among thymic surgeons in primary surgery of TETs with pleural
involvement is to add extended thymectomy. No conclusions on
the value of added basic or extended thymectomy to thymomec-
tomy at primary surgery for pleural disease of TETs for FFR can
be drawn from this study.
The large number of patients that could be collected on this
rare disease entity is one of the strengths of this study. Its
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retrospective nature is one of the weaknesses. The long study
period necessary for collecting this large cohort of patients with
this rare presentation of TETs is another limitation of this study.
Innovations in diagnostic and therapeutic modalities may change
institutional treatment practices influencing outcomes.
Prospectively collected data on all patients with TETs and pleural
involvement by ESTS/International Thymic Malignancies Interest
Group and Japanese Association for Research on the Thymus are
warranted. Nevertheless, this collaborative effort gives detailed
insights into current diagnostic and therapeutic practices of
European and Canadian thoracic surgery and underlines again
the incontestable importance of surgery for patients with primary
and recurrent TETs with pleural involvement. We recommend
close follow-up after surgery for pleural disease of TETs.
In summary, complete surgical resection is the mainstay for
treatment of patients with TETs even in Masaoka–Koga Stage IVA.
The type of resection, i.e. EPP, TP, LP, is dependent from the ex-
tent and distribution of tumour. However, even in more
advanced tumour situations with the combination of pleural and
intraparenchymal tumour spread, EPP provides equally as good
results as the less complex procedures (TP or LP) for pleural me-
tastasis only.
SUPPLEMENTARY MATERIAL
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APPENDIX. CONFERENCE DISCUSSION
Dr M. Okumura (Osaka, Japan): I congratulate Dr Moser and colleagues for creat-
ing this large database of 152 patients undergoing surgical treatment for pleural
dissemination of thymic epithelial tumours. I also agree with the indication of sur-
gery for Stage IVA thymomas and resectable recurrent thymomas. I hope that the
authors’ tremendous efforts will lead to an adequate treatment strategy for dis-
semination of thymic epithelial tumours. But I have 3 points that I need to clarify.
The first question is on the indication of surgery for thymic carcinoma. Thymic
carcinoma was shown to be an independent significant factor for poor outcome
in overall survival, cause-specific survival and freedom from recurrence in this
study. The hazard ratio was 6.5, 13.1 and 2.4, respectively, in each of the analyses.
Five-year freedom from recurrence is approximately 10%. These results might sug-
gest that surgery is not indicated for pleural dissemination of thymic carcinoma.
I would like to know the authors’ opinion about the indication for pleural dis-
semination of thymic carcinoma. If you think that operative indication is still justi-
fied, then please let us know the condition in which surgery for dissemination of
thymic carcinoma can be chosen.
The next question concerns completeness of resection. In the present study,
cases undergoing R0 resection were shown to have better survival compared
with R1/R2 resection. In resection of pleural lesions, it is sometimes difficult to
discriminate R0 resection from R1 resection and to predict whether R0 resection
can be obtained before surgery. I would like to know whether even R1 resection
shows a significant difference compared with R2 resection or not.
The final question relates to operative procedures to resect pleural dissemin-
ation. There was no significant difference in either overall survival or freedom
from recurrence among extrapleural pneumonectomy, total pleurectomy and
local pleurectomy. If so, the least invasive procedure, local pleurectomy, should
be chosen for any patient. As you mentioned, I guess that this result was obtained
depending on the surgeon’s adequate selection of patients and operative proced-
ures. If the present study is able to suggest the choice of operative procedure in
specific situations, please let me know.
Dr Moser: You have read the study very closely. The first question was about
thymic carcinoma. It is correct. We found (and this is not surprising as we saw
this in other studies) that in thymic carcinoma, overall survival, cause-specific sur-
vival and freedom from recurrence are also worse in this study.
I am not giving guidelines: all the data are here, and I cannot give a recom-
mendation for individual patients. But as a surgeon, I still treat patients, not statis-
tics. I have this data in my mind, and my goal in every patient with thymic
carcinoma is to achieve an R0, a complete resection, preferring surgery, because
the data show that these people will have prolonged survival. So I would go for
surgery also in thymic carcinoma patients with the goal of achieving a complete
resection. If this is not possible, incompletely resected patients do much worse.
The second question concerned the resection status. To make this feasible for
the study, we did it like others before. We only took patients with pathologically
confirmed complete resections. So when the pathologist stated in one of the
multiple centres, in Canada, Italy, Austria, that this was a complete resection, then
we took this for the analysis of freedom from recurrence. We did not include pa-
tients who had incomplete resection after R1 resection, and who may have had a
complete remission after postoperative therapy, in the analysis of freedom from
recurrence. We wanted to have this as clean as possible, so we only took the
pathologically confirmed complete resections in this study. We thought this
would be the cleanest approach.
And your third question was about the procedures. I showed you a comparison
of extrapleural pneumonectomy with the procedures of total pleurectomy and local
pleurectomy. There is an obvious bias in the choice of these procedures. EPP is only
chosen by the surgeon if there is metastasis to the lung, to the pleural surfaces, the
pericardium, the diaphragm. Then, the patient needs an EPP. And a local pleurec-
tomy is only chosen if there is smaller metastatic or oligometastatic disease.
This is not a randomized comparison of surgical procedures. This is not the
message. But the message for me is that even with this invasive surgery, EPP, you
can achieve as good a result if you do a complete resection as after such a local
pleurectomy where you just resect one or two nodules from the pleura. That is
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really surprising to me. So it is really worth going for radical surgery in advanced
disease. This is the message that I get out of it. I don’t want to say that patients
who have local pleurectomy get the same result as EPP. This is not what this figure
tells us. This tells us patients had the right operation and it had a good outcome.
Dr A. Oliaro (Torino, Italy): You have reported 5 plications of the diaphragm
for phrenic nerve involvement. In the Torino experience, we never suture the
phrenic nerve after resection, because we don’t believe in suture of the phrenic
nerve. But last month, we resected the nerve and we sutured the nerve, and the
phrenic nerve now functions; the diaphragm is functional. What do you think
about that? Is it necessary to have a study if we must suture the nerve or we cut
the nerve and we plicate the diaphragm?
Dr Moser: This is very interesting. You are talking about phrenic nerve recon-
struction, as I understand it. I never did a phrenic nerve reconstruction. In these
patients with extensive disease, the phrenic nerve was obviously involved. I don’t
know the length of the phrenic nerve that was resected or whether there was a
possibility for phrenic nerve reconstruction, but in non-EPP patients it is maybe
worth following this concept.
Dr J. Schirren (Wiesbaden, Germany): It would be interesting for me to know
how many patients you looked at in the beginning of the ’70s. I think the surgical
technique in the ’70s was not the same as in the ’90s or in the 2000s. Therefore, it
would be interesting to know how many patients were from this era.
Dr Moser: As I showed on one of the introductory slides, 90% of the patients
had their pleural surgery between 2001 and 2014. There were just a few patients
from back then.
Dr Schirren: But how many had an EPP in the beginning of the ’70s?
Dr Moser: I cannot tell you, but, as I said, most patients, 90% of them, were
from between 2001 and 2014. So it is just a couple of patients, maybe 1 or 2
EPPs, from the period you mention.
Dr Schirren: The chemotherapy that patients get for this extended disease is
different between the ’70s and the ’80s and the ’90s and nowadays, and, there-
fore, I can’t believe that there is no difference between an EPP and a
pleurectomy, and the patients get carboplatin and etoposide. This is very aggres-
sive chemotherapy. I think we all know from mesothelioma that there are
differences.
Dr Moser: Of course the chemotherapy changes, but I have to say that the
most predominant chemotherapeutic scheme was the PAC scheme, so the
cisplatin-based scheme. This was more than 80%. There is not much change over
the years in this. You saw that about 60% had neoadjuvant therapy, so multimo-
dality therapy was quite frequent here.
But this is not a study on chemotherapy. This is a surgical study. This is just
data that we collected to have a detailed picture. There was no complete remis-
sion. There were partial remissions for the neoadjuvant therapy in about half of
the patients, but not one complete remission. We have all this data, but I can’t
show it. You just gave me 8 mins here.
Dr A. Toker (Istanbul, Turkey): We have pleural involvement with thymoma,
around 40 cases, and according to our experience, which we reviewed very re-
cently, it is not uncommon that lymph node metastases occurred in these
patients.
I would like to know the number of obtained lymph node metastases in these
patients and your attitude towards the lymph node in pleurectomy situations. Do
you also do lymph node dissections in those patients who have recurred?
Dr Moser: I think in open surgery you always do lymph node dissection.
I cannot tell you the extent of lymph node dissection in this multicentre retro-
spective collection of data, but just a handful of lymph node metastases were re-
ported. As you would expect in thymomas, there are not many lymph node
metastases.
Dr S. Bo¨lu¨kbas (Wuppertal, Germany): I have a comment. If you have lymph
node metastases, then it is upstaging to IVB, not IVA, therefore you have to ex-
clude those patients.
Dr Moser: Absolutely, but this is not a study just on IVA. This is a study on all
patients with pleural disease and their recurrences.
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